Therefore, prevention of ACh deprivation by inhibiting acetylcholine-degrading enzymes, cholinesterases (acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)) could be a therapeutic target for AD3. Here, BCHE is linked to Alzheimer disease 3.